Books, Journals, New Media Section Editor: Harriet
S. Meyer, MD, Contributing Editor, JAMA; David H. Morse, MS, University
of Southern California, Norris Medical Library, Journal Review Editor.
In 1998, Neil Ruzic, a scientist, inventor, science publisher, and journalist,
was diagnosed with mantle cell lymphoma (MCL), a particularly deadly form
of non-Hodgkin lymphoma of which it comprises 5% to 10%. Although MCL appears
to be phenotypically indolent (and was previously classified as intermediate
lymphocytic or small–clear cell lymphoma), it behaves aggressively.
It is characterized by a unique chromosomal abnormality, t(11;14) (q13;q32),
which approximates the bcl-1 oncogene at the 11q13
locus to the immunoglobulin heavy-chain locus at 14q32. This translocation
leads to overexpression of cyclin D1, which regulates the transition from
the G1 to S phase of the cell cycle.
Bitran JD. Cancer Cure. JAMA. 2004;291(5):626-627. doi:10.1001/jama.291.5.626